Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphatic Diseases AND Bone Marrow Failure AND Leukemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    112 result(s) found for: Lymphatic Diseases AND Bone Marrow Failure AND Leukemia. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2011-001845-34 Sponsor Protocol Number: AMBIHOW Start Date*: 2011-09-15
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: LIPOSOMAL AMPHOTERICIN B (AMBISOME) 10 mg/kg once a week for 10 weeks as maintenance antifungal therapy for Proven/Probable Invasive Fungal Infection in hematologic patients with Acute Myeloid Leuk...
    Medical condition: Proven/Probable Invasive Fungal Infection in hematologic patients with Acute Myeloid Leukaemia and/or in Allogeneic Hematopoietic Stem Cell Transplant recipients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10061730 Bone marrow transplant PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    14.1 10005329 - Blood and lymphatic system disorders 10028484 Mycoses fungoides HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002365-37 Sponsor Protocol Number: 3066K1-1165 Start Date*: 2012-04-04
    Sponsor Name:J.W. Goethe-University
    Full Title: A double-blind, placebo-controlled, randomized, multicenter phase II trial to assess the efficacy of temsirolimus added to standard primary therapy in elderly patients with newly diagnosed AML
    Medical condition: Patients with newly diagnosed AML (except APL) according to the FAB and WHO classification, including AML evolving from MDS and AML after previous cytotoxic therapy or radiation (secondary AML) Bo...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000878 Acute myeloblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000693-18 Sponsor Protocol Number: ActD-AML-PG01 Start Date*: 2014-05-27
    Sponsor Name:Dipartimento di Medicina, Università di Perugia
    Full Title: A PHASE II STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF ACTINOMYCIN D IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH NUCLEOPHOSMIN (NPM1) GENE MUTATION
    Medical condition: Relapsed/refractory acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003608-11 Sponsor Protocol Number: RG_12-125 Start Date*: 2014-02-20
    Sponsor Name:University of Birmingham
    Full Title: IciCLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI-32765) in B-cell Receptor Pathway Inhibition in CLL.
    Medical condition: Chronic Lymphocytic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10009310 CLL LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-000074-19 Sponsor Protocol Number: GCP#03.01.020 Start Date*: 2014-10-24
    Sponsor Name:Gamida Cell Ltd
    Full Title: Full title of the trial: Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescents and Adult Patients with Hematologic...
    Medical condition: High risk haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    17.0 100000004864 10025316 Lymphoma NOS LLT
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    17.0 100000004864 10009015 Chronic myeloid leukemia LLT
    17.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002216-40 Sponsor Protocol Number: CML1516 Start Date*: 2016-10-04
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: BOSUTINIB EFFICACY SAFETY TOLERABILITY (BEST) STUDY IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS FAILING FRONT-LINE TREATMENT WITH OTHER TYROSINE KINASE INHIBITORS
    Medical condition: Chronic Myeloid Leukemia (CML) in Chronic Phase
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001102-34 Sponsor Protocol Number: CML1315 Start Date*: 2015-09-15
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Optimizing Ponatinib USe (OPUS). Studio GIMEMA di fase 2 sull¿efficacia e sul profilo di rischio di ponatinib, 30 mg al giorno, in pazienti con Leucemia Mieloide Cronica (LMC) in Fase Cronica, resi...
    Medical condition: Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003778-15 Sponsor Protocol Number: 20130265 Start Date*: 2017-11-08
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 1b/2 Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Horai Study)
    Medical condition: relapsed/refractory B-precursor Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    20.0 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004714-25 Sponsor Protocol Number: REALIB-LLA-2017 Start Date*: 2018-07-25
    Sponsor Name:Fundación PETHEMA
    Full Title: Phase I-II trial, open and nonrandomized, to assess the role of Idelalisib in patients with acute lymphoblastic leukemia (ALL) relapsed or refractory to other treatments, and in elderly patients wi...
    Medical condition: Acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-018314-75 Sponsor Protocol Number: MT103-203 Start Date*: 2010-08-05
    Sponsor Name:Amgen Research (Munich) GmbH
    Full Title: A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor...
    Medical condition: minimal residual disease (MRD) of B-precursor ALL
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003871-20 Sponsor Protocol Number: AML1819 Start Date*: 2020-02-26
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Phase III study to assess the impact of gemtuzumab ozogamicin, in combination with standard chemotherapy, on the levels of minimal residual disease, and the role of glasdegib as a post-transplant m...
    Medical condition: Favorable-intermediate-risk Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005159-14 Sponsor Protocol Number: GC P#02.01.001 Start Date*: 2008-04-15
    Sponsor Name:Gamida Cell-Teva Joint Venture Ltd.
    Full Title: A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in ...
    Medical condition: High-risk haematological malignancies (including AML, ALL, CML, NHL, HD, and MDS) with an indication for allogeneic haematopoietic stem cell transplantation, to support haematopoietic reconstitutio...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    9.1 10009015 Chronic myeloid leukemia LLT
    9.1 10001690 ALL LLT
    9.1 10028533 Myelodysplastic syndrome LLT
    9.1 10020206 Hodgkin's disease LLT
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    9.1 10001756 Allogenic bone marrow transplantation therapy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-018419-14 Sponsor Protocol Number: CAMN107A2120 Start Date*: 2010-10-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with ...
    Medical condition: pediatric patients with Gleevec® (imatinib)- resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with refractory/relapsed Ph+ ALL
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009700 CML LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001955-35 Sponsor Protocol Number: RG_11-054 Start Date*: 2012-02-15
    Sponsor Name:University of Birmingham
    Full Title: Single Arm Phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) as non-toxic therapy against myeloid and lymphoid cancers
    Medical condition: Acute Myeloid Leukaemia (AML), Chronic Lymphocytic Leukaemia (CLL) and B-cell Non-Hodgkins Lymphoma (BNHL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005758-36 Sponsor Protocol Number: UTX-TGR-304 Start Date*: 2016-10-28
    Sponsor Name:TG Therapeutics
    Full Title: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chr...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007587-21 Sponsor Protocol Number: CLL10 Start Date*: 2008-09-05
    Sponsor Name:University of Cologne
    Full Title: Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocyti...
    Medical condition: patients (age 18 years or older) with chronic lymphocytic leukemia: Stage Binet C or stage Binet B and A requiring treatment
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) DK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-004672-11 Sponsor Protocol Number: SNOXA12C201 Start Date*: 2012-03-05
    Sponsor Name:NOXXON Pharma AG
    Full Title: A multi-centre, open label, uncontrolled, Phase IIa clinical trial evaluating the safety and efficiacy of NOX-A12 in combination with a background therapy of bendamustine and rituximab (BR) in prev...
    Medical condition: Relapsed chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000677-89 Sponsor Protocol Number: CIMJ995A12101 Start Date*: 2022-11-18
    Sponsor Name:Novartis Pharma AG
    Full Title: Phase I, open label, multicenter, dose escalation and expansion study of IMJ995 in Acute Lymphoblastic Leukemia
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10024290 Leukaemias acute lymphocytic HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-002761-35 Sponsor Protocol Number: LAL1811 Start Date*: 2012-11-14
    Sponsor Name:INCYTE Biosciences International Sarl
    Full Title: Trattamento di prima linea della Leucemia Linfoblastica Acuta (LLA) Philadelphia positiva (Ph+)/BCR/ABL+ con un nuovo potente inibitore delle Tirosin-chinasi (TKI), AP24534 (Ponatinib). Studio mult...
    Medical condition: Ph positive (Ph+)/Bcr-Abl positive Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000684-13 Sponsor Protocol Number: LLC1215 Start Date*: 2015-09-18
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: A Phase II study of the combination of Ofatumumab and Ibrutinib followed by allogeneic bone marrow transplant or consolidation for pretreated high risk patients with Chronic Lymphocytic Leukemia
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 09:00:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA